000			04103nam a2200325 i 4500
999			_c399359 _d399359
001			399359
003			ES-MaUEC
005			20240415170619.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			230306s2023 sz | fo |||| 0|eng d
020			_a9783031158483
024	7		_a10.1007/978-3-031-15848-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRS199.5 _b2023 EB
245	0	0	_aMalarial Drug Delivery Systems : _bAdvances in Treatment of Infectious Diseases _cedited by Ranjita Shegokar, Yashwant Pathak
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aMalaria: Cellular Understanding of Disease -- Drug Resistance, Statistics and Patent Status -- Malaria: Current Treatment Options -- Polymeric Nanoparticles in Malaria -- Solid Lipid Nanoparticles in Malaria -- Dendrimers in Malaria -- Liposomes in Malaria -- Micro and Nano Emulsions in Malaria -- Nanosuspension in Malaria -- Alginate and Gelatin Nanoparticles in Malaria -- Niosomes in Malaria -- Metal Nanoparticles in Malaria -- Nanotechnology in Malaria Diagnosis -- Nanotechnology-based Vaccination -- Herbal Platforms in Malaria -- Surface-modified Drug Delivery Systems in Malaria,- Clinical Trials in Malaria -- Malaria-Overall Picture -- New Drugs in Synthesis Research for Malaria -- Disease Models In Malaria Research.
520			_aThe disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause of significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity that almost always comes at the cost of impaired immunity. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems The theme of the first book is Malaria. This book compiles the complete road map of malarial drug delivery systems by understanding the pathophysiology of the disease, the current state of malaria across the globe, new clinical trials, emerging drugs, and the development of novel drug delivery platforms. Various novel micro-and nano-formulations using promising technologies are being explored to deliver the malarial drug via different administration routes. This book addresses the gap between new approaches and old treatment modalities and how the former is superior in pharmacological performance when tested in in-vitro and in-vivo. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of malarial research.
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9667667 _aSistemas de liberación de fármacos
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-15848-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b04/2024 _dz _eb _zSI